• Eric B Suhler, Alfredo Adán, Antoine P Brézin, Eric Fortin, Hiroshi Goto, Glenn J Jaffe, Toshikatsu Kaburaki, Michal Kramer, Lyndell L Lim, Cristina Muccioli, Quan Dong Nguyen, Joachim Van Calster, Luca Cimino, Martina Kron, Alexandra P Song, Jianzhong Liu, Sophia Pathai, Anne Camez, Ariel Schlaen, Mirjam E J van Velthoven, Albert T Vitale, Manfred Zierhut, Samir Tari, and Andrew D Dick.
• Oregon Health & Science University, Casey Eye Institute, Portland, Oregon, and VA Portland Health Care System, Portland, Oregon. Electronic address: suhlere@ohsu.edu.
• Ophthalmology. 2018 Jul 1; 125 (7): 1075-1087.

PurposeTo evaluate safety and efficacy of adalimumab in patients with noninfectious intermediate, posterior, or panuveitis.DesignPhase 3, open-label, multicenter clinical trial extension (VISUAL III).ParticipantsAdults meeting treatment failure (TF) criteria or who completed VISUAL I or II (phase 3, randomized, double-masked, placebo-controlled) without TF.MethodsPatients received adalimumab 40 mg every other week. Interim follow-up data were described from VISUAL III weeks 0 through 78.Main Outcome MeasuresDisease quiescence, steroid-free quiescence, active inflammatory chorioretinal/retinal vascular lesions, anterior chamber cell grade, vitreous haze grade, best-corrected visual acuity (BCVA), and corticosteroid dose. Binary data were reported using nonresponder imputation (NRI), continuous data using last observation carried forward and as-observed analysis, and corticosteroid dose using observed-case analysis. Adverse events (AEs) were reported from first adalimumab dose in VISUAL III through interim cutoff.ResultsOf 424 patients enrolled, 371 were included in intent-to-treat analysis. At study entry, 242 of 371 (65%) patients had active uveitis; 60% (145/242, NRI) achieved quiescence at week 78, and 66% (95/143, as-observed) of those were corticosteroid free. At study entry, 129 of 371 (35%) patients had inactive uveitis; 74% (96/129, NRI) achieved quiescence at week 78, and 93% (89/96, as-observed) of those were corticosteroid free. Inflammatory lesions, anterior chamber grade, and vitreous haze grade showed initial improvement followed by decline in patients with active uveitis and remained stable in patients with inactive uveitis. BCVA improved in patients with active uveitis from weeks 0 to 78 (0.27 to 0.14 logMAR; left and right eyes; as-observed) and remained stable in patients with inactive uveitis. Mean corticosteroid dose decreased from 13.6 mg/day (week 0) to 2.6 mg/day (week 78) in patients with active uveitis and remained stable in those with inactive uveitis (1.5-1.2 mg/day). AEs (424 events/100 patient-years) and serious AEs (16.5 events/100 patient-years) were comparable with previous VISUAL trials.ConclusionsPatients with active uveitis at study entry who received adalimumab therapy were likely to achieve quiescence, improve visual acuity, and reduce their daily uveitis-related systemic corticosteroid use. Most patients with inactive uveitis at study entry sustained quiescence without a systemic corticosteroid dose increase. No new safety signals were identified.Copyright © 2018 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

28 keywords...

hide…